Literature DB >> 23329811

Modeling boundary conditions for balanced proliferation in metastatic latency.

Donald P Taylor1, Jakob Z Wells, Andrej Savol, Chakra Chennubhotla, Alan Wells.   

Abstract

PURPOSE: Nearly half of cancer metastases become clinically evident five or more years after primary tumor treatment; thus, metastatic cells survived without emerging for extended periods. This dormancy has been explained by at least two countervailing scenarios: cellular quiescence and balanced proliferation; these entail dichotomous mechanistic etiologies. To examine the boundary parameters for balanced proliferation, we conducted in silico modeling. EXPERIMENTAL
DESIGN: To illuminate the balanced proliferation hypothesis, we explored the specific boundary probabilities under which proliferating micrometastases would remain dormant. A two-state Markov chain Monte Carlo model simulated micrometastatic proliferation and death according to stochastic survival probabilities. We varied these probabilities across 100 simulated patients each with 1,000 metastatic deposits and documented whether the micrometastases exceeded one million cells, died out, or remained dormant (survived 1,218 generations).
RESULTS: The simulations revealed a narrow survival probability window (49.7-50.8%) that allowed for dormancy across a range of starting cell numbers, and even then for only a small fraction of micrometastases. The majority of micrometastases died out quickly even at survival probabilities that led to rapid emergence of a subset of micrometastases. Within dormant metastases, cell populations depended sensitively on small survival probability increments.
CONCLUSIONS: Metastatic dormancy as explained solely by balanced proliferation is bounded by very tight survival probabilities. Considering the far larger survival variability thought to attend fluxing microenvironments, it is more probable that these micrometastatic nodules undergo at least periods of quiescence rather than exclusively being controlled by balanced proliferation. ©2013 AACR.

Entities:  

Mesh:

Year:  2013        PMID: 23329811      PMCID: PMC3594128          DOI: 10.1158/1078-0432.CCR-12-3180

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  23 in total

1.  Assessing convergence of Markov chain Monte Carlo simulations in hierarchical Bayesian models for population pharmacokinetics.

Authors:  Michael G Dodds; Paolo Vicini
Journal:  Ann Biomed Eng       Date:  2004-09       Impact factor: 3.934

Review 2.  Dormancy of solitary metastatic cells.

Authors:  Jason L Townson; Ann F Chambers
Journal:  Cell Cycle       Date:  2006-08-15       Impact factor: 4.534

3.  The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis.

Authors:  Simone Mocellin; Dave Hoon; Alessandro Ambrosi; Donato Nitti; Carlo Riccardo Rossi
Journal:  Clin Cancer Res       Date:  2006-08-01       Impact factor: 12.531

4.  Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases.

Authors:  K J Luzzi; I C MacDonald; E E Schmidt; N Kerkvliet; V L Morris; A F Chambers; A C Groom
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

5.  Systemic cancer progression and tumor dormancy: mathematical models meet single cell genomics.

Authors:  Christoph A Klein; Dieter Hölzel
Journal:  Cell Cycle       Date:  2006-08-15       Impact factor: 4.534

6.  The problem of cancer dormancy: understanding the basic mechanisms and identifying therapeutic opportunities.

Authors:  Julio A Aguirre-Ghiso
Journal:  Cell Cycle       Date:  2006-08-15       Impact factor: 4.534

7.  Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy.

Authors:  George N Naumov; Ian C MacDonald; Pascal M Weinmeister; Nancy Kerkvliet; Kishore V Nadkarni; Sylvia M Wilson; Vincent L Morris; Alan C Groom; Ann F Chambers
Journal:  Cancer Res       Date:  2002-04-01       Impact factor: 12.701

Review 8.  Tumor-vascular interactions and tumor dormancy.

Authors:  George N Naumov; Judah Folkman; Oddbjorn Straume; Lars A Akslen
Journal:  APMIS       Date:  2008 Jul-Aug       Impact factor: 3.205

9.  The evolution of tumor metastases during clonal expansion.

Authors:  Hiroshi Haeno; Franziska Michor
Journal:  J Theor Biol       Date:  2009-11-14       Impact factor: 2.691

10.  Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.

Authors:  Bernard Fisher; Stewart Anderson; John Bryant; Richard G Margolese; Melvin Deutsch; Edwin R Fisher; Jong-Hyeon Jeong; Norman Wolmark
Journal:  N Engl J Med       Date:  2002-10-17       Impact factor: 91.245

View more
  17 in total

Review 1.  Systems Biology of Cancer Metastasis.

Authors:  Yasir Suhail; Margo P Cain; Kiran Vanaja; Paul A Kurywchak; Andre Levchenko; Raghu Kalluri
Journal:  Cell Syst       Date:  2019-08-28       Impact factor: 10.304

Review 2.  The great escape: How metastases of melanoma, and other carcinomas, avoid elimination.

Authors:  Alan Wells; Amanda Clark; Andrew Bradshaw; Bo Ma; Howard Edington
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-06

Review 3.  Mechanisms of disseminated cancer cell dormancy: an awakening field.

Authors:  María Soledad Sosa; Paloma Bragado; Julio A Aguirre-Ghiso
Journal:  Nat Rev Cancer       Date:  2014-08-14       Impact factor: 60.716

4.  Hepatic nonparenchymal cells drive metastatic breast cancer outgrowth and partial epithelial to mesenchymal transition.

Authors:  Donald P Taylor; Amanda Clark; Sarah Wheeler; Alan Wells
Journal:  Breast Cancer Res Treat       Date:  2014-03-09       Impact factor: 4.872

Review 5.  The dormancy dilemma: quiescence versus balanced proliferation.

Authors:  Alan Wells; Linda Griffith; Jakob Z Wells; Donald P Taylor
Journal:  Cancer Res       Date:  2013-06-21       Impact factor: 12.701

6.  Autophagy in breast cancer metastatic dormancy: Tumor suppressing or tumor promoting functions?

Authors:  Alyssa La Belle Flynn; William P Schiemann
Journal:  J Cancer Metastasis Treat       Date:  2019-05-14

Review 7.  A microphysiological system model of therapy for liver micrometastases.

Authors:  Amanda M Clark; Sarah E Wheeler; Donald P Taylor; Venkateswaran C Pillai; Carissa L Young; Rachelle Prantil-Baun; Transon Nguyen; Donna B Stolz; Jeffrey T Borenstein; Douglas A Lauffenburger; Raman Venkataramanan; Linda G Griffith; Alan Wells
Journal:  Exp Biol Med (Maywood)       Date:  2014-05-12

Review 8.  Targeting tumor cell motility as a strategy against invasion and metastasis.

Authors:  Alan Wells; Jelena Grahovac; Sarah Wheeler; Bo Ma; Douglas Lauffenburger
Journal:  Trends Pharmacol Sci       Date:  2013-04-06       Impact factor: 14.819

Review 9.  All-human microphysical model of metastasis therapy.

Authors:  Sarah E Wheeler; Jeffrey T Borenstein; Amanda M Clark; Mohammad R Ebrahimkhani; Ira J Fox; Linda Griffith; Walker Inman; Douglas Lauffenburger; Transon Nguyen; Venkateswaran C Pillai; Rachelle Prantil-Baun; Donna B Stolz; Donald Taylor; Theresa Ulrich; Raman Venkataramanan; Alan Wells; Carissa Young
Journal:  Stem Cell Res Ther       Date:  2013-12-20       Impact factor: 6.832

Review 10.  Computational systems biology in cancer brain metastasis.

Authors:  Huiming Peng; Hua Tan; Weiling Zhao; Guangxu Jin; Sambad Sharma; Fei Xing; Kounosuke Watabe; Xiaobo Zhou
Journal:  Front Biosci (Schol Ed)       Date:  2016-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.